Table 1.
GenoScreen Deeplex® MycTB tNGS targets amplified for tNGS by drug compound and critical concentration used in pDST *
| Drug | Gene targets | Critical concentration (μg/mL) |
|---|---|---|
| INH | katG, inhA, fabG1, ahpC | 0.1 |
| RIF | rpoB | 1.0 |
| EMB | embB | 5.0 |
| PZA | pncA | 100.0 |
| SM | rrs, rpsL, gidB | 1.0 |
| FQ | gyrA, gyrB | LVX (1.0), MFX-low (0.25, MFX-high (1.0) |
| KM | eis, rrs | 2.5 |
| AMK | rrs | 1.0 |
| CPM | rrs, tlyA | 2.5 |
| ETH | ethA, fabG1, inhA | 5.0 |
| LZD | rplC, rrl | 1.0 |
| CFZ | rv0678 | 1.0 |
*
Bedaquiline pDST was not routine at the time of the study and was therefore not performed.
tNGS = targeted next-generation sequencing; pDST = phenotypic drug susceptibility testing; INH=isoniazid; RIF = rifampicin; EMB = ethambutol; PZA = pyrazinamide; SM = streptomycin; FQ = fluoroquinolone; KM = kanamycin; AMK = amikacin; CPM = capreomycin; ETH = ethionamide; LZD = linezolid; CFZ = clofazimine.